Despite advances in our understanding of the genetic, immunologic and environmental factors that contribute to the etiopathogenesis of ulcerative colitis, there is still no pathognomonic marker ...

MB310 has been developed as an oral capsule, dosed once daily, containing a defined consortium of eight live gut commensal bacterial strains. It is designed to deliver long-term remission to UC ...

Approximately 15% of patients with ulcerative colitis develop an acute attack of severe colitis, and 30% of these patients require colectomy. Severe ulcerative colitis is therefore considered a ...

With over 250 peer-reviewed publications, he has made significant contributions to medical literature, shedding light on the treatment and understanding of ulcerative colitis and Crohn's disease.

SAN FRANCISCO -- Research presented at the annual Crohn's and Colitis Congress included studies comparing the effectiveness ...

Pharmaceutical ads are difficult to avoid in American television programming and a growing number of them promote a class of ...

"There is a pressing need to modernize traditional endoscopic assessments in IBD to enhance precision and efficiency in ulcerative colitis research," said Mark Genovese, MD, Senior Vice President of ...

Ulcerative colitis is a chronic, immune-mediated disorder of the colon and rectum characterized by mucosal inflammation that damages the bowel wall surface. Current therapeutic options include ...

[5] After exclusions of such diseases as infectious colitis, bacillary dysentery, amebiasis, chronic schistosomiasis, intestinal tuberculosis, Crohn's disease, ischemic colitis and radiation ...

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than Humira’s 20% at the same time point.